Israel's Compugen, a company that focuses on clinical-stage cancer immunotherapy company and predictive target discovery, has added immune-oncology pioneer Dr. Nils Longers to its Scientific Advisory Board, the company announced Wednesday.
Compugen's lead product candidate, COM701, a first-in-class anti-PVRIG antibody for the treatment of solid tumors, is undergoing a Phase 1 clinical study.
Follow Israel Hayom on Facebook and Twitter
"We are honored to have Dr. Lonberg join Compugen's Scientific Advisory Board. His work provided the basis for a revolution in the treatment of cancer and laid the earliest foundation for the field of cancer immunotherapy, paving the way for companies like Compugen to pursue this path and potentially make a difference in the lives of patients with cancer," said Compugen President and CEO Dr. Anat Cohen-Dayag.
